Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06194539

Assessing the Fertility Status of Men With Spinal Muscular Atrophy (SMA)

This study will aim to assess the fertility status of men with Spinal Muscular Atrophy (SMA) not on disease-modifying therapies.

Participants will:

1. Complete online questionnaires that will assess SMA diagnosis and disease burden, medical and surgical history, medication usage, and fertility status and perspectives. 2. Over the 3-month initial study baseline period participants will provide two separate ejaculates for semen analysis and a single determination of sperm quality using DNA fragmentation testing using home collection and subsequent shipment to a central laboratory. 3. Over the initial study baseline period of 3 months study participants will obtain a blood test to determine male reproductive hormone levels.

During the 24-month study duration, participants will be requested to undergo a yearly semen analysis and complete online relevant questionnaires.

Recruiting

Interested in participating?

Request Info

Key information

About this study

Study participants will:

  • Complete online questionnaires that will assess SMA diagnosis and disease burden, medical and surgical history, medication usage, and fertility status and perspectives.
  • Over the 3-month initial study baseline period participants will provide two separate ejaculates for semen analysis and a single determination of sperm quality using DNA fragmentation testing using home collection and subsequent shipment to a central laboratory.
  • Over the initial study baseline period of 3 months study participants will obtain a blood test to determine male reproductive hormone levels.

During the 24-month study duration, participants will be requested to undergo a yearly semen analysis and complete online relevant questionnaires.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Signed Informed Consent Form (or assent)
  • Male and age greater than 18 years and less than 50 years of age with a confirmed diagnosis of SMA at the time of signing the Informed Consent Form (or assent)
  • Currently not on a disease-modifying agent or therapy for SMA
  • Adequately recovered from any acute illness at the time of screening, and considered clinically well enough to participate in the study.

Exclusion criteria

Men with a prior history of chemotherapy, radiation therapy, prostate or testicular cancer, undescended testicles and use of anabolic steroids or testosterone usage will be excluded

Treatment and study plan

Primary outcomes

  1. Semen Volume

    Time frame: Two semen samples will be obtained at the initial 3 month study enrollment and then annually for the duration of the study period of 24 months

    Home collected semen ejaculates will be obtained to measure semen volume (normal > 1.5ml)

  2. Sperm Concentration

    Time frame: Two semen samples will be obtained at the initial 3 month study enrollment and then annually for the duration of the study period of 24 months

    Home collected semen ejaculates will be obtained to measure sperm concentration ( normal > 15 million sperm/ml)

  3. Sperm Motility

    Time frame: Two semen samples will be obtained at the initial 3 month study enrollment and then annually for the duration of the study period of 24 months

    Home collected semen ejaculates will be obtained to measure sperm motility ( normal > 39% motile sperm)

  4. Sperm Morphology

    Time frame: Two semen samples will be obtained at the initial 3 month study enrollment and then annually for the duration of the study period of 24 months

    Home collected semen ejaculates will be obtained to measure sperm morphology (normal > 4% normal sperm morphology)

  5. Sperm DNA Fragmentation Assay

    Time frame: At intial 3 month study enrollment

    Home collected semen ejaculates will be obtained to measure sperm DNA fragmentation rate ( normal < 30% DNA fragmented sperm)

Secondary outcomes

  1. Male Reproductive Hormones - Total Testosterone Level

    Time frame: At intial 3 month study enrollment

    Serum total testosterone level will be obtained where normal values are 250 -1100 ng/dL

  2. Male Reproductive Hormones - Free Testosterone Level

    Time frame: At intial 3 month study enrollment

    Serum free testosterone level will be obtained where normal values are 46.0 - 224.0 pg/mL

  3. Male Reproductive Hormones - Follicle Stimulating Hormone

    Time frame: At intial 3 month study enrollment

    Serum FSH ( Follicle StimulatingHormone) level will be obtained where normal values are 1.6 -8.0 mIU/mL

  4. Male Reproductive Hormones - Luteinizing Hormone

    Time frame: At intial 3 month study enrollment

    Serum LH ( Luteinizing Hormone) level will be obtained where normal values are 1.5- 9.3 mIU/mL

  5. Male Reproductive Hormones - Estradiol

    Time frame: At intial 3 month study enrollment

    Serum Estradiol level will be obtained where normal values are < 39 pg/mL

Study contacts

Contact information is provided by the study sponsor or research team.

Natan Bar-Chama, MD

CONTACT

[email protected]

2016941781

Sponsors and collaborators

Lead sponsor

Bar-Chama, Natan, M.D.

Other

Registry information

Official study title

The Assessment of Fertility in Men With Spinal Muscular Atrophy (SMA)

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Jan 8, 2024
Registry last updated
Jan 8, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.